-
Product Insights
New![]()
Net Present Value Model: 4D Pharma Plc’s MRx-4DP0004
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: 4D Pharma Plc’s MRx-518
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Company Insights
New![]()
Innovation and Patenting activity of 4D Molecular Therapeutics Inc Q3 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of 4D Molecular Therapeutics Inc Q3 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – 4D-110 in Choroideremia
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.4D-110 in ChoroideremiaDrug Details:4D-110 is under development for the treatment of choroideremia. The therapy is administered...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – 4D-710 in Cystic Fibrosis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.4D-710 in Cystic Fibrosis Drug Details:4D-710 is under development for the treatment of cystic fibrosis. It...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – 4D-125 in Retinitis Pigmentosa (Retinitis)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.4D-125 in Retinitis Pigmentosa (Retinitis) Drug Details:4D-125 is under development for the treatment of X-linked retinitis...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – 4D-150 in Diabetic Macular Edema
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. 4D-150 in Diabetic Macular Edema Drug Details: 4D-150 is under development for the treatment wet...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – 4D-150 in Wet (Neovascular / Exudative) Macular Degeneration
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. 4D-150 in Wet (Neovascular / Exudative) Macular Degeneration Drug Details: 4D-150 is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Zatolmilast in Traumatic Brain Injury
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Zatolmilast in Traumatic Brain InjuryDrug Details:BPN-14770 is under development for the treatment of fragile X syndrome,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Zatolmilast in Fragile X Syndrome
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Zatolmilast in Fragile X SyndromeDrug Details:BPN-14770 is under development for the treatment of fragile X syndrome,...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.